Document Detail


Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
MedLine Citation:
PMID:  20854954     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Clinical outcomes in patients with acute coronary syndromes randomized in the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial who underwent percutaneous coronary intervention (PCI) of saphenous vein grafts (SVGs) were examined. The ACUITY trial assessed the safety and efficacy of bivalirudin alone versus bivalirudin plus a glycoprotein (GP) IIb/IIIa inhibitor versus heparin plus a GP IIb/IIIa inhibitor in 13,819 patients with moderate- and high-risk acute coronary syndromes, 7,789 of whom underwent PCI. A total of 329 patients (4.2%) underwent PCI of SVGs in ACUITY. The primary end points at 30 days were composite ischemia or major adverse cardiac events (death, myocardial infarction, or unplanned target vessel revascularization), major bleeding (unrelated to coronary artery bypass grafting), and net adverse clinical events (composite ischemia or major bleeding). The rates of ischemic, bleeding, and net clinical end points were similar with bivalirudin monotherapy, bivalirudin plus a GP IIb/IIIa inhibitor, and heparin plus a GP IIb/IIIa inhibitor. Net adverse clinical outcome rates at 30 days were 22%, 26%, and 22% (p = 0.67), respectively, for the 3 groups. Major adverse cardiac event rates at 1 year were 37%, 37%, and 43% (p = 0.95), respectively. Minor bleeding unrelated to coronary artery bypass grafting at 30 days was significantly lower with bivalirudin alone compared with heparin plus a GP IIb/IIIa inhibitor (26% vs 38%, p = 0.05). In conclusion, bivalirudin is an effective anticoagulant in PCI of SVGs in acute coronary syndromes, with similar rates of major adverse cardiac events and net adverse cardiac events and lower minor bleeding complications in comparison with heparin plus a GP IIb/IIIa inhibitor or bivalirudin plus a GP IIb/IIIa inhibitor.
Authors:
Dinesh Kumar; George Dangas; Roxana Mehran; Ajay Kirtane; Michel Bertrand; Ramin Ebrahimi; Giulio Guagliumi; Somjot Brar; Martin Fahy; Eric Heller; Jeffrey Moses; Gregg Stone
Related Documents :
11206014 - Calming the plaque to delay intervention for 24 hours in acute coronary syndromes.
22813874 - Neurological benefit of therapeutic hypothermia following return of spontaneous circula...
1322434 - Pharmacodynamics, clinical indications, and adverse effects of heparin.
11251354 - Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-t...
17382734 - The effect of the choice of irrigation fluid on cardiac stress during transurethral res...
1569904 - The role of the lymphatic system in coronary atherosclerosis.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-08-17
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-09-21     Completed Date:  2010-10-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  941-5     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010. Published by Elsevier Inc.
Affiliation:
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy,  surgery*
Aged
Anticoagulants / administration & dosage*
Coronary Artery Bypass*
Drug Therapy, Combination
Female
Heparin / administration & dosage*
Hirudins / administration & dosage*
Humans
Male
Peptide Fragments / administration & dosage*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Recombinant Proteins / administration & dosage
Saphenous Vein / transplantation
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Hirudins; 0/Peptide Fragments; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 128270-60-0/bivalirudin; 9005-49-6/Heparin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of radiation dose and the effect of operator experience in femoral and radial arterial ac...
Next Document:  Comparison of drug-eluting and bare metal stents for saphenous vein graft lesions (from the National...